Search research articles
Contact Us
Filters
Showing results (241-250 of 251) with videos related to
Page
of 26
Sort By:
Frontiers in Oncology
|
August 27, 2019
Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma
Xiaohong Han, Qiaoyun Tan, Sheng Yang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 14, 2018
Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study
Fei Qi, Wei-Hu Wang, Xiao-Hui He, et al.
Frontiers in Pharmacology
|
July 25, 2022
Dexmedetomidine Attenuates Ferroptosis-Mediated Renal Ischemia/Reperfusion Injury and Inflammation by Inhibiting ACSL4 <i>via</i> α2-AR
Wen-Hui Tao, Xi-Sheng Shan, Jia-Xin Zhang, et al.
Cancer Pathogenesis and Therapy
|
February 8, 2024
Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005-2018)
Yuankai Shi, Haizhu Chen, Yan Qin, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 17, 2015
Altered cofactor regulation with disease-associated p97/VCP mutations
Xiaoyi Zhang, Lin Gui, Xiaoyan Zhang, et al.
Annals of Hematology
|
July 7, 2022
Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma
Fei Qi, Yan Xie, Dedao Wang, et al.
Signal Transduction and Targeted Therapy
|
April 26, 2026
Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study
Lin Gui, Haifeng Liu, Huaqing Wang, et al.
Zhonghua Yi Xue Za Zhi
|
November 1, 2022
[Survival and prognosis analysis of patients with Hodgkin lymphoma treated with standard treatment paradigm]
Y K Shi, X H Tao, Y He, et al.
Cancer Treatment Reviews
|
November 18, 2025
Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma
Liqiong Xue, Tingting Xu, Guochun Cao, et al.
Hematological Oncology
|
July 20, 2022
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera<sup>®</sup> ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial
Yuankai Shi, Qingyuan Zhang, Xiaonan Hong, et al.
Page
of 26
Search research articles
Search
Showing results (241-250 of 251) with videos related to
Sort By:
Page
of 26
Frontiers in Oncology
|
August 27, 2019
Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I-III Lung Adenocarcinoma
Xiaohong Han, Qiaoyun Tan, Sheng Yang, et al.
International Journal of Radiation Oncology, Biology, Physics
|
August 14, 2018
Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study
Fei Qi, Wei-Hu Wang, Xiao-Hui He, et al.
Frontiers in Pharmacology
|
July 25, 2022
Dexmedetomidine Attenuates Ferroptosis-Mediated Renal Ischemia/Reperfusion Injury and Inflammation by Inhibiting ACSL4 <i>via</i> α2-AR
Wen-Hui Tao, Xi-Sheng Shan, Jia-Xin Zhang, et al.
Cancer Pathogenesis and Therapy
|
February 8, 2024
Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005-2018)
Yuankai Shi, Haizhu Chen, Yan Qin, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
March 17, 2015
Altered cofactor regulation with disease-associated p97/VCP mutations
Xiaoyi Zhang, Lin Gui, Xiaoyan Zhang, et al.
Annals of Hematology
|
July 7, 2022
Comparison analysis of first-line asparaginase- versus non-asparaginase-based regimens for early-stage extranodal NK/T-cell lymphoma
Fei Qi, Yan Xie, Dedao Wang, et al.
Signal Transduction and Targeted Therapy
|
April 26, 2026
Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study
Lin Gui, Haifeng Liu, Huaqing Wang, et al.
Zhonghua Yi Xue Za Zhi
|
November 1, 2022
[Survival and prognosis analysis of patients with Hodgkin lymphoma treated with standard treatment paradigm]
Y K Shi, X H Tao, Y He, et al.
Cancer Treatment Reviews
|
November 18, 2025
Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma
Liqiong Xue, Tingting Xu, Guochun Cao, et al.
Hematological Oncology
|
July 20, 2022
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera<sup>®</sup> ) in combination with CHOP in patients with previously untreated CD20-positive diffuse large B-cell lymphoma: A randomized, single-blind, phase III clinical trial
Yuankai Shi, Qingyuan Zhang, Xiaonan Hong, et al.
Page
of 26